Rapid Dose Therapeutics Corp.

OTCPK:RDTC.F Stock Report

Market Cap: US$17.9m

Rapid Dose Therapeutics Past Earnings Performance

Past criteria checks 0/6

Rapid Dose Therapeutics has been growing earnings at an average annual rate of 16.6%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 20.2% per year.

Key information

16.6%

Earnings growth rate

27.4%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate20.2%
Return on equityn/a
Net Margin-400.1%
Last Earnings Update31 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Rapid Dose Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:RDTC.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Aug 241-540
31 May 241-530
29 Feb 241-430
30 Nov 231-430
31 Aug 231-320
31 May 231-330
28 Feb 231-430
30 Nov 221-950
31 Aug 221-1050
31 May 221-950
28 Feb 222-850
30 Nov 212-230
31 Aug 212-220
31 May 212-120
28 Feb 211-220
30 Nov 200-220
31 Aug 20-1-530
31 May 200-540
29 Feb 200-870
30 Nov 190-1770
31 Aug 191-1570
31 May 190-1460
28 Feb 190-1130
30 Nov 180-320
31 Aug 180-220

Quality Earnings: RDTC.F is currently unprofitable.

Growing Profit Margin: RDTC.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RDTC.F is unprofitable, but has reduced losses over the past 5 years at a rate of 16.6% per year.

Accelerating Growth: Unable to compare RDTC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDTC.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).


Return on Equity

High ROE: RDTC.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:39
End of Day Share Price 2024/12/11 00:00
Earnings2024/08/31
Annual Earnings2024/02/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rapid Dose Therapeutics Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter-Thilo HaslerSphene Capital GmbH